G
GigaGen
Overcoming Immune Dysregulation to Fight Disease
About GigaGen
GigaGen operates in the biotechnology sector, specializing in antibody drug discovery using advanced single cell technology. The company serves pharmaceutical companies and research institutions by providing high affinity antibodies for therapeutic use. GigaGen's core technology captures and recreates complete immune repertoires as functional antibody libraries, enabling the discovery of rare, high affinity antibodies that are crucial for treating diseases such as cancer and infectious diseases. The company uses microfluidics and molecular genomics to identify and develop these antibodies, offering a natively paired antibody library that yields drug leads with higher sensitivity and specificity compared to traditional methods. GigaGen's business model involves partnering with pharmaceutical companies for the development and commercialization of antibody-based therapies, generating revenue through licensing agreements and milestone payments. The company also focuses on developing its own proprietary antibody therapies, such as the GIGA 2050 recombinant anti-coronavirus immunoglobulin, to address urgent medical needs.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2010
- Headquarters
- San Carlos, United States
- Employees
- 55
- Open positions
- 2
- Dealroom signal
- 78.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Microfluidics, Genetics and genomics, Genome Engineering, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning GigaGen.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2021 | $80M | $115M | Grifols | — |
| LATE VC✓Equity / VC | Jul 2017 | $35M | $45M | Grifols | — |
Growth signals
Latest recorded traffic for GigaGen is 3.3K monthly website visits, up 83.3% over the last three months. GigaGen's team grew 61.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
US National Science Foundation
Series B and later1 investor entered at this stage
Grifols
Other known investors4 additional known investors
California Life Sciences
Small Business Innovation Research
StartX
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about GigaGen on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See GigaGen’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.